FSHD - Facioscapulohumeral Muscular Dystrophy Clinical Trial
— HIT-FSHDOfficial title:
High Intensity Interval Training in Patients With Facioscapulohumeral Muscular Dystrophy
The investigators aim to investigate the effect of high-intensity training in patients with facioscapulohumeral muscular dystrophy. Can patients benefit from this type of exercise without muscle damage.
Status | Completed |
Enrollment | 18 |
Est. completion date | September 2015 |
Est. primary completion date | September 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Diagnosed with Facioscapulohumeral muscular dystrophy or - healthy matched control, matched for age, gender, BMI and activity level. Exclusion Criteria: - More than 1 hour cardiac exercise weekly before inclusion. - Pregnant or breastfeeding women. - Physical or mental condition, which could influence the results. - Participating in other studies, which could influence the results. - Physical or mental condition, which prevent participating in the study protocol. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
Denmark | Copenhagen Neuromuscular Center, department of Neurology, Rigshospitalet | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Grete Andersen, MD |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incremental test | An incremental test is performed at baseline (week 1), after 4 weeks interval training, in the end of 8 weeks interval training, and after another 8 week of individual home based training. The primary outcome is change from baseline in maximal oxygen consumption and work load. | week 1,6,11 and 18 | No |
Secondary | Physical function | We measure changes from baseline in muscle strength, walking speed and the ability to rise up from a chair. Muscle strength is measured by a hand-held dynamometer. Walking speed is measured by a 6 minute walk test. The ability to rise up from a chair is measured by a 5-times-sit-to-stand-test. |
baseline, week 6,11 and 18 | No |
Secondary | Self-assessment | Changes between run-in period (week 1-2) and the first intervention period (week 3-11). Participants evaluate pain, muscle fatigue and daily activity level every day using a visual analog scale (VAS). |
Every day in week 1-11 | Yes |
Secondary | Creatine Kinase | Creatine Kinase (CK) is measure in plasma at week 1,6,11 and 18 in all participants. In the supervised training participants CK is also measured once a week doing the 8 weeks of supervised training. | week 1,6,11 and 18 | Yes |
Secondary | Activity level | Change in activity level from baseline is measure as step/day. Participants is wearing a pedometer for seven days. | baseline, week 10 and week 18. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02159612 -
1 Year MRI Followup in Facioscapulohumeral Muscular Dystrophy
|
N/A |